Cargando…
1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454396/ http://dx.doi.org/10.1016/j.annonc.2021.08.1551 |
| _version_ | 1784570484359168000 |
|---|---|
| author | Thomas, S.J. Perez, J.L. Lockhart, S.P. Hariharan, S. Kitchin, N. Bailey, R. Liau, K. Lagkadinou, E. Türeci, Ö. Şahin, U. Xu, X. Dychter, S.S. Lu, C. Gentile, T. Gruber, W. |
| author_facet | Thomas, S.J. Perez, J.L. Lockhart, S.P. Hariharan, S. Kitchin, N. Bailey, R. Liau, K. Lagkadinou, E. Türeci, Ö. Şahin, U. Xu, X. Dychter, S.S. Lu, C. Gentile, T. Gruber, W. |
| author_sort | Thomas, S.J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8454396 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84543962021-09-21 1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine Thomas, S.J. Perez, J.L. Lockhart, S.P. Hariharan, S. Kitchin, N. Bailey, R. Liau, K. Lagkadinou, E. Türeci, Ö. Şahin, U. Xu, X. Dychter, S.S. Lu, C. Gentile, T. Gruber, W. Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2021-09 2021-09-21 /pmc/articles/PMC8454396/ http://dx.doi.org/10.1016/j.annonc.2021.08.1551 Text en Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Thomas, S.J. Perez, J.L. Lockhart, S.P. Hariharan, S. Kitchin, N. Bailey, R. Liau, K. Lagkadinou, E. Türeci, Ö. Şahin, U. Xu, X. Dychter, S.S. Lu, C. Gentile, T. Gruber, W. 1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine |
| title | 1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine |
| title_full | 1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine |
| title_fullStr | 1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine |
| title_full_unstemmed | 1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine |
| title_short | 1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine |
| title_sort | 1558o covid-19 vaccine in participants (ptcpts) with cancer: subgroup analysis of efficacy/safety from a global phase iii randomized trial of the bnt162b2 (tozinameran) mrna vaccine |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454396/ http://dx.doi.org/10.1016/j.annonc.2021.08.1551 |
| work_keys_str_mv | AT thomassj 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT perezjl 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT lockhartsp 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT hariharans 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT kitchinn 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT baileyr 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT liauk 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT lagkadinoue 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT turecio 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT sahinu 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT xux 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT dychterss 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT luc 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT gentilet 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine AT gruberw 1558ocovid19vaccineinparticipantsptcptswithcancersubgroupanalysisofefficacysafetyfromaglobalphaseiiirandomizedtrialofthebnt162b2tozinameranmrnavaccine |